8-K: Nu Skin Enterprises Reports Q4 and Full-Year 2024 Results Above Revenue Guidance; Provides Initial 2025 Outlook

Nu Skin Enterprises announced Q4 and full-year 2024 financial results exceeding revenue guidance, with a focus on strengthening the core business and accelerating growth in developing markets in 2025.

Summary

• Nu Skin Enterprises reported Q4 2024 revenue of $445.6 million, an 8.8% decrease year-over-year, but above the company's guidance.
• Rhyz revenue increased by 27.7% to $83.1 million in Q4 2024.
• The company's Q4 2024 EPS was $(0.73), or $0.38 excluding restructuring and other charges.
• Full-year 2024 revenue was $1.73 billion, a 12.0% decrease compared to 2023.
• Full-year 2024 EPS was $(2.95), or $0.84 excluding restructuring and other charges.
• Nu Skin anticipates Q1 2025 revenue between $345 and $365 million and full-year 2025 revenue between $1.48 and $1.62 billion.
• The company expects a negative foreign currency impact of approximately 3% in both Q1 and full-year 2025.
• Nu Skin sold Mavely for $250 million, strengthening the balance sheet.
• The company is focusing on strengthening its core Nu Skin business and accelerating growth in developing markets.
• Nu Skin plans to introduce Prysm iO, an intelligent wellness device, later in 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company beat revenue guidance and is optimistic about future growth, the year-over-year declines in revenue and earnings, along with economic challenges, temper the positive outlook.

Positives

• Nu Skin exceeded its Q4 2024 revenue guidance.
• Rhyz revenue showed strong growth, increasing by 27.7% in Q4 2024.
• The sale of Mavely for $250 million strengthened the company's balance sheet.
• Nu Skin is focusing on strengthening its core business and expanding into developing markets.
• The introduction of Prysm iO is expected to drive future growth in the nutrition side of the business.

Negatives

• Q4 2024 revenue decreased by 8.8% year-over-year.
• Q4 2024 EPS was negative at $(0.73), although it was $0.38 excluding restructuring and other charges.
• Full-year 2024 revenue decreased by 12.0% compared to 2023.
• Full-year 2024 EPS was negative at $(2.95), although it was $0.84 excluding restructuring and other charges.
• The company anticipates continued economic challenges and poor consumer sentiment, particularly in Greater China and South Korea.

Risks

• Failure of new initiatives or products to generate interest among the sales force and customers.
• Changes in direct selling laws and regulations, particularly in the United States and Mainland China.
• Economic conditions and events globally could negatively impact the business.
• Competitive pressures in the company's markets.
• Adverse publicity related to the company, products, or industry.
• Political, legal, tax, and regulatory uncertainties, especially in Mainland China and other international markets.
• Uncertainty regarding meeting restrictions and government scrutiny in Mainland China.
• Risk of foreign-currency fluctuations.
• Uncertainties regarding the future financial performance of acquired businesses.
• Risks related to accurately predicting and delivering sufficient quantities of products.
• Regulatory risks associated with the company's products.
• Adverse results of tax audits or unfavorable changes to tax laws.

Future Outlook

Nu Skin anticipates improving business trends and a return to year-over-year growth in several markets in 2025, with full-year revenue guidance of $1.48 to $1.62 billion and adjusted EPS of $0.90 to $1.30, excluding the gain from the sale of Mavely. Q1 2025 revenue is projected at $345 to $365 million.

Management Comments

• Ryan Napierski, Nu Skin president and CEO, stated that the company was pleased to beat Q4 revenue guidance and exceed adjusted earnings after materially completing the restructuring plan.
• James D. Thomas, chief financial officer, mentioned that the company is better positioned to execute its strategy and drive earnings growth in 2025 due to the executed restructuring plan and improved cost structure.

Industry Context

Nu Skin operates in the competitive beauty and wellness industry, facing challenges from economic conditions and consumer sentiment, particularly in key markets like Greater China and South Korea. The company is focusing on strengthening its core business and expanding into developing markets to drive growth.

Comparison to Industry Standards

• It is difficult to compare Nu Skin's performance directly to industry standards without specific competitor data.
• However, companies like Herbalife, Amway, and Avon operate in similar direct selling models.
• Nu Skin's focus on beauty devices and nutritional products aligns with trends in the wellness industry.
• The growth of Rhyz indicates a diversification strategy similar to that of other large consumer goods companies.

Stakeholder Impact

• Shareholders: Potential for improved earnings and growth in the future, but current results show declines.
• Employees: Restructuring plan may have impacted employment, but the company is focused on future growth.
• Customers: Introduction of new products like Prysm iO may enhance customer experience.
• Sales Force: Changes to the compensation plan and focus on developing markets may impact sales force activities.

Next Steps

• Continued rollout of the enhanced sales performance compensation plan in several markets.
• Accelerating growth in developing markets, including Latin America.
• Introduction of Prysm iO, an intelligent wellness device, later in 2025.

Key Dates

Keywords

Nu Skin, Rhyz, Revenue, Earnings Per Share, Financial Results, Guidance, Restructuring, Mavely, Prysm iO, Direct Selling